NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
51 hedge funds and large institutions have $9.56M invested in NeuBase Therapeutics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 7 closing their positions.
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
2% more funds holding
Funds holding: 50 → 51 (+1)
28% less capital invested
Capital invested by funds: $13.3M → $9.56M (-$3.77M)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
60% less call options, than puts
Call options by funds: $395K | Put options by funds: $984K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$271K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$166K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$72.8K |
| 4 |
Renaissance Technologies
New York
|
+$69.1K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.18M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$390K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$299K |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$216K |
| 5 |
D.E. Shaw & Co
New York
|
-$167K |
NBSE Hedge Fund Activity: Q2 2016 in Review
51 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2016, worth a combined $9.56M — down 28% from $13.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new NBSE positions and 7 closed out — a net gain of 2 holders — while 7 added to existing stakes and 11 trimmed.
The largest buyer was United Capital Financial Advisors, opening a new position worth an estimated $271K. The largest seller was Opaleye Management, exiting entirely with an estimated $1.18M sold.
- 51 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2016, up from 50 in Q1 2016.
- Funds reported $9.56M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2016, down 28% quarter-over-quarter.
- 9 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2016 and 7 closed out, a net change of +2 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2016 was United Capital Financial Advisors, an estimated $271K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2016 was Opaleye Management, an estimated $1.18M sold.
Based on aggregated 13F filings for Q2 2016.